Hydroxy Urea

Phase 3Small molecule

BBeni-Suef University

Hydroxy Urea is one of 26 small molecule programs targeting Thalassemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThalassemiaRecruiting

ThalassemiaPhase 3

Recruiting

Competition

Competitive Landscape

28 competitors in Thalassemia

#DrugCompanyPhaseTrials

Exjade

Novartis

Approved

11 2

Reblozyl

Bristol-Myers Squibb

Approved

8 3

Thalomid

Bristol-Myers Squibb

Approved

5 4

Cellcept

Roche

Approved

4 5

Desferal

Jazz Pharmaceuticals

Approved

3 6

Trexall

Jazz Pharmaceuticals

Approved

3 7

Fludara

Sanofi

Approved

3 8

Simulect

Novartis

Approved

2 9

Zometa

Pfizer

Approved

1 10

Prograf

VVeloxis Pharmaceuticals

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Thalassemia

NCT07673302

Q4 2027

Not yet recruiting

Sickle Cell

NCT07785752

Clinical

Trials by Indication[1]

Thalassemia2 trials

Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of Transfusion Dependent Thalassemia in Children: A Quasi-Randomised Clinical Trial

Recruiting·—·Phase 4·NCT06299670·90 enrolled

Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia: a Prospective 12 Months Study

Recruiting·RRiphah International University·Preclinical·NCT07673302·240 enrolled

Anemia1 trial

Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia

Completed·—·Phase 2/3·NCT04301336·350 enrolled

Sickle Cell1 trial

Clinical Utility of Urinary N-Acetyl-β-D-Glucosaminidase (NAG), Kidney Injury Molecule-1 (KIM-1), and Diffusion-Weighted Renal MRI for the Early Detection of Sickle Cell Nephropathy in Children

Not yet recruiting·AAssiut University··NCT07785752·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Hydroxy Urea. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hydroxy Urea compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hydroxy Urea. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beni-Suef University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeni-Suef University

Hydroxy Urea

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Trials by Indication[1]

Thalassemia2 trials

Anemia1 trial

Sickle Cell1 trial

References

Drug Info

Quick Facts

Related News